In the fall of 2022, mainstream media started warning of a potential “tripledemic,” with COVID,1 seasonal influenza and respiratory syncytial virus (RSV)2 being in circulation at the same time. Fear sells, they say, and that’s certainly the adage used by Big Pharma when it comes to vaccines.
The sudden focus on RSV in particular, which has been around for decades, just so happened to coincide with announcements that RSV vaccines were being fast-tracked — a risky venture if there ever was one, considering vaccine makers have been trying to bring an RSV vaccine to market for about 60 years, and couldn’t due to safety issues.
Not surprisingly, Pfizer and Moderna are also working on combination mRNA jabs for COVID, RSV and the flu,3 currently expected to hit the market in 2024 and/or 2025.4 The U.S. Food and Drug Administration approved the first-ever RSV vaccines in the summer of 2023 for seniors 60 years and older — one by Pfizer (Abrysvo)5 and one by GlaxoSmithKline (Arexvy).6
Both vaccines are recombinant subunit vaccines, meaning certain viral proteins are used to trigger an immune response,7 and both manufacturers have reported Guillain-Barré syndrome as a side effect of their shots.8
Pfizer’s RSV vaccine will likely cost somewhere between $180 and $270, while GSK intends on charging $200 to $295.9 GSK had initially announced a price tag of $148 per dose, but decided to double the price due to newer data suggesting effectiveness may carry into a second season.
Tripledemic Propaganda Continues
As we’re heading into the fall of 2023, the “tripledemic” of COVID, RSV and influenza is again making headlines. A Google search for the key words “triple pandemic 2023”10 garnered a staggering 41.2 million articles as of mid-August 2023.
I WILL NOT COMPLY !!!!
NEITHER WILL I !!!!!!